In addition to conventional factors, such as age, sex, and body mass index (BMI), there is increasing consensus by experts and scholars on the influence of Hashimoto’s thyroiditis (HT) and BRAF V600E mutations on central lymph node metastasis (CLNM) in patients with papillary thyroid carcinoma (PTC). Here, BRAF is linked to Hashimoto thyroiditis.